A Study of Indoximod or Placebo Plus Pembrolizumab or Nivolumab for Subjects With Unresectable or Metastatic Melanoma
Clinical trial NCT03301636 · TERMINATED
Trial details
- NCT number
- NCT03301636
- Sponsor
- NewLink Genetics Corporation
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-12-08
- Primary completion
- 2019-10-21
- Enrollment
- 21
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.